2.48
price up icon2.06%   0.05
after-market アフターアワーズ: 2.46 -0.02 -0.81%
loading
前日終値:
$2.43
開ける:
$2.45
24時間の取引高:
3.18M
Relative Volume:
0.76
時価総額:
$607.34M
収益:
$194.75M
当期純損益:
$-51.26M
株価収益率:
-8.8571
EPS:
-0.28
ネットキャッシュフロー:
$-23.38M
1週間 パフォーマンス:
+6.90%
1か月 パフォーマンス:
+50.30%
6か月 パフォーマンス:
+29.17%
1年 パフォーマンス:
+92.25%
1日の値動き範囲:
Value
$2.35
$2.50
1週間の範囲:
Value
$2.35
$2.90
52週間の値動き範囲:
Value
$0.80
$2.90

Akebia Therapeutics Inc Stock (AKBA) Company Profile

Name
名前
Akebia Therapeutics Inc
Name
セクター
Healthcare (1148)
Name
電話
617-871-2098
Name
住所
245 FIRST STREET, CAMBRIDGE, MA
Name
職員
181
Name
Twitter
@akebiatx
Name
次回の収益日
2024-11-07
Name
最新のSEC提出書
Name
AKBA's Discussions on Twitter

AKBA を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Drug Manufacturers - Specialty & Generic icon
AKBA
Akebia Therapeutics Inc
2.48 607.34M 194.75M -51.26M -23.38M -0.28
Drug Manufacturers - Specialty & Generic icon
ZTS
Zoetis Inc
160.41 66.72B 9.29B 2.52B 2.28B 5.57
Drug Manufacturers - Specialty & Generic icon
HLN
Haleon Plc Adr
10.45 48.08B 14.35B 1.85B 0 0.4023
Drug Manufacturers - Specialty & Generic icon
TAK
Takeda Pharmaceutical Co Adr
13.72 47.74B 30.08B 710.16M 4.45B 0.2182
Drug Manufacturers - Specialty & Generic icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
17.48 18.49B 16.54B -1.64B 749.00M -1.45
Drug Manufacturers - Specialty & Generic icon
UTHR
United Therapeutics Corp
308.07 13.31B 2.99B 1.21B 1.13B 25.06

Akebia Therapeutics Inc Stock (AKBA) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-04-28 開始されました Leerink Partners Outperform
2025-04-01 開始されました Jefferies Buy
2023-11-29 再開されました BTIG Research Buy
2023-08-28 アップグレード H.C. Wainwright Neutral → Buy
2023-05-31 アップグレード Piper Sandler Neutral → Overweight
2022-03-31 ダウングレード H.C. Wainwright Buy → Neutral
2022-03-31 ダウングレード Mizuho Buy → Neutral
2022-03-31 ダウングレード Needham Buy → Hold
2022-03-31 ダウングレード Piper Sandler Overweight → Neutral
2021-03-08 開始されました Cantor Fitzgerald Overweight
2021-01-29 ダウングレード JP Morgan Neutral → Underweight
2019-11-14 繰り返されました Needham Buy
2019-08-06 繰り返されました H.C. Wainwright Buy
2019-07-11 繰り返されました H.C. Wainwright Buy
2019-05-02 開始されました JP Morgan Overweight
2019-03-20 開始されました Citigroup Neutral
2018-09-07 再開されました Morgan Stanley Equal-Weight
2018-08-10 繰り返されました Needham Buy
2018-06-06 繰り返されました H.C. Wainwright Buy
2017-12-19 開始されました Piper Jaffray Overweight
2017-12-07 開始されました BTIG Research Buy
2017-09-15 開始されました RBC Capital Mkts Sector Perform
2017-07-10 繰り返されました H.C. Wainwright Buy
2017-04-27 繰り返されました H.C. Wainwright Buy
2017-04-27 繰り返されました Needham Buy
2016-12-27 繰り返されました H.C. Wainwright Buy
2016-12-20 繰り返されました JMP Securities Mkt Outperform
2016-11-15 開始されました Aegis Capital Buy
2016-09-29 開始されました Brean Capital Buy
2016-03-16 繰り返されました Needham Buy
2016-01-21 開始されました Credit Suisse Neutral
すべてを表示

Akebia Therapeutics Inc (AKBA) 最新ニュース

pulisher
May 13, 2025

Akebia Therapeutics to Present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference - GlobeNewswire

May 13, 2025
pulisher
May 10, 2025

Akebia projects Vafseo rollout to double patient access by Q4 2025 - MSN

May 10, 2025
pulisher
May 10, 2025

Akebia Therapeutics, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next - simplywall.st

May 10, 2025
pulisher
May 10, 2025

Akebia Therapeutics First Quarter 2025 Earnings: Beats Expectations - Yahoo Finance

May 10, 2025
pulisher
May 09, 2025

Akebia Therapeutics, Inc. (NASDAQ:AKBA) Q1 2025 Earnings Call Transcript - Insider Monkey

May 09, 2025
pulisher
May 09, 2025

Akebia Therapeutics: Q1 Earnings Snapshot - New Haven Register

May 09, 2025
pulisher
May 09, 2025

Akebia Therapeutics Inc (AKBA) Q1 2025 Earnings Call Highlights: Strong Revenue Performance and ... - Yahoo Finance

May 09, 2025
pulisher
May 09, 2025

Akebia Therapeutics Inc (AKBA) Q1 2025 Earnings Call Highlights: Strong Revenue Performance and ... By GuruFocus - Investing.com Canada

May 09, 2025
pulisher
May 09, 2025

Akebia Therapeutics Inc (AKBA) Q1 2025 Earnings Call Highlights: Strong Revenue Performance and Strategic Market Penetration - GuruFocus

May 09, 2025
pulisher
May 09, 2025

Akebia Therapeutics Reports Strong Q1 2025 Performance - TipRanks

May 09, 2025
pulisher
May 08, 2025

Akebia Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights - GlobeNewswire

May 08, 2025
pulisher
May 08, 2025

Akebia Therapeutics Q1 2025 Earnings Call Transcript - MarketBeat

May 08, 2025
pulisher
May 08, 2025

Transcript : Akebia Therapeutics, Inc., Q1 2025 Earnings Call, May 08, 2025 - marketscreener.com

May 08, 2025
pulisher
May 08, 2025

Akebia Therapeutics (AKBA) Sees Strong Q1 Revenue Growth Fueled by Vafseo - GuruFocus

May 08, 2025
pulisher
May 08, 2025

Akebia Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView

May 08, 2025
pulisher
May 08, 2025

Earnings call transcript: Akebia Therapeutics beats Q1 2025 estimates, stock surges - Investing.com Australia

May 08, 2025
pulisher
May 08, 2025

Akebia Therapeutics (AKBA) Q1 Earnings and Revenues Top Estimates - Yahoo Finance

May 08, 2025
pulisher
May 08, 2025

Akebia (AKBA) Surpasses Revenue Expectations with Strong Vafseo Debut | AKBA Stock News - GuruFocus

May 08, 2025
pulisher
May 08, 2025

Akebia Therapeutics Inc Q1 2025 Earnings: EPS of $0.04, Revenue Surges to $57.3 Million, Beating Estimates - GuruFocus

May 08, 2025
pulisher
May 08, 2025

Akebia Therapeutics, Inc. SEC 10-Q Report - TradingView

May 08, 2025
pulisher
May 08, 2025

Akebia Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com

May 08, 2025
pulisher
May 07, 2025

Earnings To Watch: Akebia Therapeutics Inc (AKBA) Reports Q1 2025 Result - Yahoo Finance

May 07, 2025
pulisher
May 06, 2025

Akebia Therapeutics Announces Multiple Positive Business Updates - ADVFN

May 06, 2025
pulisher
May 04, 2025

There's No Escaping Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) Muted Revenues Despite A 38% Share Price Rise - simplywall.st

May 04, 2025
pulisher
May 04, 2025

Vadadustat Alternative Dosing Study Results Published in the American Journal of Kidney Disease - ADVFN

May 04, 2025
pulisher
May 02, 2025

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(4) - marketscreener.com

May 02, 2025
pulisher
May 02, 2025

Akebia Therapeutics to Report First Quarter 2025 Financial Results and Discuss Recent Business Highlights - marketscreener.com

May 02, 2025
pulisher
May 01, 2025

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

May 01, 2025
pulisher
May 01, 2025

Akebia Therapeutics Expands Team: Grants $2.41 Stock Options to 8 New Strategic Hires - Stock Titan

May 01, 2025
pulisher
May 01, 2025

Akebia Therapeutics (AKBA) Expected to Beat Earnings Estimates: Should You Buy? - Yahoo Finance

May 01, 2025
pulisher
May 01, 2025

Akebia Therapeutics, Inc. Announces First Quarter 2025 Financial Results Release and Conference Call Details - Nasdaq

May 01, 2025
pulisher
May 01, 2025

Akebia Therapeutics to Report First Quarter 2025 Financial Results and Discuss Recent Business ... - Bluefield Daily Telegraph

May 01, 2025
pulisher
Apr 28, 2025

Akebia (AKBA) Secures Strong Position with Vafseo Launch for Ane - GuruFocus

Apr 28, 2025
pulisher
Apr 28, 2025

Leerink raises Akebia stock to outperform with $7 target By Investing.com - Investing.com Canada

Apr 28, 2025
pulisher
Apr 28, 2025

Leerink Partners Initiates Coverage of Akebia Therapeutics (AKBA) with Outperform Recommendation - Nasdaq

Apr 28, 2025
pulisher
Apr 28, 2025

Akebia (AKBA) Secures Strong Position with Vafseo Launch for Anemia Treatment | AKBA Stock News - GuruFocus

Apr 28, 2025
pulisher
Apr 28, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 28, 2025
pulisher
Apr 26, 2025

U.S. Renal Care Enrolled First Patients in the VOICE Collaborative Clinical Trial of Vafseo® (vadadustat) for CKD Patients on Dialysis - ADVFN

Apr 26, 2025
pulisher
Apr 16, 2025

Lobbying Update: $45,000 of AKEBIA THERAPEUTICS INC. lobbying was just disclosed - Nasdaq

Apr 16, 2025
pulisher
Apr 10, 2025

Why You Shouldn't Bet Against Akebia Therapeutics (AKBA) Stock - Barchart.com

Apr 10, 2025
pulisher
Apr 09, 2025

US High Growth Tech Stocks to Watch in 2023 - Yahoo Finance

Apr 09, 2025
pulisher
Apr 06, 2025

Akebia Therapeutics : Reports Second Quarter 2021 Financial Results and Highlights Recent Company Milestones - MarketScreener

Apr 06, 2025
pulisher
Apr 04, 2025

Akebia Therapeutics gets EU positive recommendation for Xoanacyl - MSN

Apr 04, 2025
pulisher
Apr 04, 2025

Akebia Therapeutics Announces Positive Opinion of European - GlobeNewswire

Apr 04, 2025
pulisher
Apr 03, 2025

EMA panel endorses Akebia’s kidney disease treatment By Investing.com - Investing.com Australia

Apr 03, 2025
pulisher
Apr 03, 2025

EMA panel endorses Akebia’s kidney disease treatment - Investing.com India

Apr 03, 2025
pulisher
Apr 03, 2025

Akebia Therapeutics Says EMA Panel Recommends Approval of Xoanacyl for Chronic Kidney Disease Treatment - MarketScreener

Apr 03, 2025

Akebia Therapeutics Inc (AKBA) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$30.84
price down icon 1.38%
$78.95
price down icon 0.72%
$8.79
price down icon 1.90%
$116.87
price down icon 2.96%
drug_manufacturers_specialty_generic RDY
$14.10
price up icon 1.22%
$308.07
price down icon 0.88%
大文字化:     |  ボリューム (24 時間):